ERBB2 and breast carcinoma: HER2-positive breast cancers (about 20% of the cases) can be effectively treated with targeted therapies such as trastuzumab and pertuzumab (Al-Azawi et al., 2023; Huang et al., 2024; Lee and Park, 2021; Zhu et al., 2022).